Key Takeaways A phase 2b trial gave 148 adults aged 70 to 85 one infusion of donated mesenchymal stem cells or placebo. At nine months, the 200 million cell group walked 63.4 meters farther than placebo. The six-month gap of 41.3 meters did not reach statistical significance. A second open-label
Key Takeaways Moorfields and UCL researchers treated nine adults with a rare eye disease in a first-in-human clinical trial. Average eye surface scores improved from 9.4 to 5.9 at three months and held at 6.7 after 12 months. Vision rose by about five chart lines on average, but the 95%
Key Takeaways Six lung transplant patients with advanced chronic lung allograft dysfunction (CLAD) received 251 monthly stem cell infusions, with follow-up up to 58 months. All six survived 24 months, and doctors saw no serious side effects linked to the cells. Lung function did not improve at first, but the
Key Takeaways Novartis paused eight autoimmune and nerve disease trials of its rap-cel CAR-T cell therapy on August 24, 2026. Three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS). Bristol Myers Squibb had already paused its zola-cel autoimmune trials in early June after separate inflammatory reactions. No regulator has
